Steve Shuey
Publications by Year
Research Areas
Immunotherapy and Immune Responses, T-cell and B-cell Immunology, Monoclonal and Polyclonal Antibodies Research, Lymphoma Diagnosis and Treatment, Cutaneous Melanoma Detection and Management
Most-Cited Works
- → Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma(1999)368 cited
- → “Primatization” of Recombinant Antibodies for Immunotherapy of Human Diseases: A Macaque/Human Chimeric Antibody Against Human CD4(1992)86 cited
- → Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody(2002)40 cited
- Enhancement of cell-mediated immunity in melanoma patients immunized with murine anti-idiotypic monoclonal antibodies (MELIMMUNE) that mimic the high molecular weight proteoglycan antigen.(1998)
- → Human Monoclonal Antibodies Isolated from Spontaneous Epstein‐Barr Virus–Transformed Tumors of Hu‐SPL‐SCID Mice and Specific for Fusion Protein Display Broad Neutralizing Activity Toward Respiratory Syncytial Virus(1999)9 cited
- → Baseline plasma HA in PDA versus healthy subjects and effects of PEGPH20 on plasma HA in PDA subjects treated with GEM/NAB.(2016)
- → ENHANCEMENT OF CELL-MEDIATED IMMUNITY IN MELANOMA PATIENTS IMMUNIZED WITH MURINE ANTI-IDIOTYPIC MABS (MELIMMUNE)(1995)
- Safety and efficacy of the zevalin radioimmunotherapy regimen arenotdevflnlshedbyextending the time interval between rituximab infusion and zevalin injection(2000)